



## Clinical trial results:

**Phase 2 multicenter study to assess the safety and efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line therapy in patients who cannot undergo local surgery and/or radiotherapy.**

### Summary

EudraCT number	2011-002576-16
Trial protocol	FR
Global end of trial date	03 October 2016

### Results information

Result version number	v1 (current)
This version publication date	09 July 2022
First version publication date	09 July 2022

### Trial information

#### Trial identification

Sponsor protocol code	GINECO-EN102b
-----------------------	---------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	ARCAGY
Sponsor organisation address	Hôpital Hôtel-Dieu, 1, place du Parvis Notre-Dame, PARIS cedex 4, France, 75181
Public contact	Sponsor office, ARCAGY, 33 142348323, vthouviot@arcagy.org
Scientific contact	Sponsor office, ARCAGY, 33 142348323, vthouviot@arcagy.org

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 July 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	03 October 2016
Global end of trial reached?	Yes
Global end of trial date	03 October 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine the clinical efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.

Clinical efficacy will be determined by the non-progression rate at 3 or 2 months depending on the group of patients. The primary endpoint is the non-progression rate at 3 months (12 weeks) for the patient group whose disease is painless (low grade tumor = stratum 1) and the non-progression rate at 2 months (8 weeks) for the group of patients with an aggressive disease (high grade tumor = stratum 2).

Protection of trial subjects:

Cette étude a été menée selon les recommandations :

- de la loi Huriot (n°88-1138) du 20 décembre 1988 relative à la Protection des Personnes se prêtant à la Recherche Biomédicale et modifiée par la loi de santé publique (n°2004-806) du 9 août 2004,
- de la loi Informatique et Libertés n°78-17 modifiée par la loi n° 2004-801 du 6 août 2004 relative à la protection des personnes physiques à l'égard des traitements de données à caractère personnel,
- de la loi Bioéthique n° 2004-800 du 6 août 2004,
- des bonnes pratiques cliniques de la conférence internationale d'harmonisation (ICH-E6 du 17/07/1996),
- de la direction européenne (2001/20/CE) sur la conduite des essais cliniques.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 September 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 40
Worldwide total number of subjects	40
EEA total number of subjects	40

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	16
From 65 to 84 years	24
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Between December 2011 and January 2014, 40 patients were enrolled at 13 French centers. 16 patients were included at 100 mg daily. Due to high rate of grade 3/4 toxicities, the IDMC proposed to stop recruitment at 100 mg but to continue the recruitment with a lower dose of 60 mg/d. 24 patients were included at this level dose.

### Period 1

Period 1 title	OVERALL TRIAL (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Cohort 60 mg
------------------	--------------

Arm description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Arm type	Experimental
Investigational medicinal product name	Buparlisib
Investigational medicinal product code	BKM120
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60mg daily

<b>Arm title</b>	Cohort 100 mg
------------------	---------------

Arm description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Arm type	Experimental
Investigational medicinal product name	Buparlisib
Investigational medicinal product code	BKM120
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

100 mg daily

<b>Number of subjects in period 1</b>	Cohort 60 mg	Cohort 100 mg
Started	24	16
Completed	24	16

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort 60 mg
-----------------------	--------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Reporting group title	Cohort 100 mg
-----------------------	---------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Reporting group values	Cohort 60 mg	Cohort 100 mg	Total
Number of subjects	24	16	40
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	7	16
From 65-84 years	15	9	24
85 years and over	0	0	0
Age continuous			
Units: years			
median	67.1	65.2	
full range (min-max)	50.0 to 79.7	53.6 to 79.5	-
Gender categorical			
Units: Subjects			
Female	24	16	40
Male	0	0	0

## End points

### End points reporting groups

Reporting group title	Cohort 60 mg
-----------------------	--------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Reporting group title	Cohort 100 mg
-----------------------	---------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

### Primary: Rate of non progression

End point title	Rate of non progression <sup>[1]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

During the study

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics

### Statistical analyses

No statistical analyses for this end point

### Secondary: Objective response rate

End point title	Objective response rate
-----------------	-------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

During the study

### Statistical analyses

---

No statistical analyses for this end point

---

### Secondary: Progression free survival (PFS)

---

End point title	Progression free survival (PFS)
-----------------	---------------------------------

---

End point description:

End point type	Secondary
----------------	-----------

---

End point timeframe:

During the study

---

### Statistical analyses

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

During the treatment period

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	4.0
--------------------	-----

### Reporting groups

Reporting group title	Cohort 60 mg
-----------------------	--------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Reporting group title	Cohort 100mg
-----------------------	--------------

Reporting group description:

40 patients were enrolled, of which 16 patients had received BKM120 at 100mg. Due to high toxicities, the IDMC has proposed to stop recruitment at 100 mg and to continue the clinical trial with a lower dose of 60mg/d. 24 pts were newly enrolled.

Serious adverse events	Cohort 60 mg	Cohort 100mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 24 (54.17%)	12 / 16 (75.00%)	
number of deaths (all causes)	10	9	
number of deaths resulting from adverse events	3	1	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Venous thrombosis			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			

Ureteral catheterisation			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Hyperthermia			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
General physical health deterioration			
subjects affected / exposed	2 / 24 (8.33%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oedema			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug eruption			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Lung disorder			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
Depression			

subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
Transaminases increased			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic enzyme increased			
subjects affected / exposed	0 / 24 (0.00%)	3 / 16 (18.75%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Depressed level of consciousness			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Intestinal perforation			

subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abdominal pain			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cytolytic hepatitis			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis exfoliative			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash erythematous			

subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
Pain in extremity			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Lymphangitis			
subjects affected / exposed	1 / 24 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Metabolism and nutrition disorders</b>			
Hyperglycaemia			
subjects affected / exposed	2 / 24 (8.33%)	2 / 16 (12.50%)	
occurrences causally related to treatment / all	2 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Decreased appetite			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Cohort 60 mg	Cohort 100mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 24 (100.00%)	15 / 16 (93.75%)	
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	7 / 16 (43.75%) 7	
Thrombosis subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	1 / 16 (6.25%) 1	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	18 / 24 (75.00%) 18	12 / 16 (75.00%) 12	
General physical health deterioration subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	0 / 16 (0.00%) 0	
Pain subjects affected / exposed occurrences (all)	11 / 24 (45.83%) 11	6 / 16 (37.50%) 6	
Fever subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	2 / 16 (12.50%) 2	
Weight subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	4 / 16 (25.00%) 4	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	8 / 16 (50.00%) 8	
Immune system disorders Allergic reaction subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	1 / 16 (6.25%) 1	
Gastrointestinal disorders Mucositis subjects affected / exposed occurrences (all)	6 / 24 (25.00%) 6	4 / 16 (25.00%) 4	
Nausea			

subjects affected / exposed occurrences (all)	8 / 24 (33.33%) 8	6 / 16 (37.50%) 6	
Vomiting subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	3 / 16 (18.75%) 3	
Constipation subjects affected / exposed occurrences (all)	9 / 24 (37.50%) 9	3 / 16 (18.75%) 3	
Diarrhoea subjects affected / exposed occurrences (all)	9 / 24 (37.50%) 9	5 / 16 (31.25%) 5	
Abdominal pain subjects affected / exposed occurrences (all)	10 / 24 (41.67%) 10	5 / 16 (31.25%) 5	
Gastrointestinal disorder subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	2 / 16 (12.50%) 2	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	0 / 16 (0.00%) 0	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	13 / 24 (54.17%) 13	8 / 16 (50.00%) 8	
Pruritus subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	3 / 16 (18.75%) 3	
Dry skin subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	3 / 16 (18.75%) 3	
Oedema subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	5 / 16 (31.25%) 5	
Hand and foot syndrome			

subjects affected / exposed	0 / 24 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Erythema			
subjects affected / exposed	0 / 24 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Photosensitivity			
subjects affected / exposed	0 / 24 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Eyelid oedema			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Panniculitis			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Burning sensation			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Itching			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Desquamation			
subjects affected / exposed	0 / 24 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Herpes zoster			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Intertrigo			
subjects affected / exposed	0 / 24 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Psychiatric disorders			
Anxiety			



subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	6 / 16 (37.50%) 6	
Depression subjects affected / exposed occurrences (all)	10 / 24 (41.67%) 10	7 / 16 (43.75%) 7	
Infections and infestations infection without neutropenia subjects affected / exposed occurrences (all)	6 / 24 (25.00%) 6	0 / 16 (0.00%) 0	
Infection subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	3 / 16 (18.75%) 3	
Paronychia subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	1 / 16 (6.25%) 1	
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	9 / 24 (37.50%) 9	3 / 16 (18.75%) 3	
Anorexia and bulimia syndrome subjects affected / exposed occurrences (all)	9 / 24 (37.50%) 9	0 / 16 (0.00%) 0	
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	10 / 16 (62.50%) 10	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 May 2013	Change dose from 10 mg to 60 mg

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported